PMID- 31749802
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood 
      and Marrow Transplantation.
PG  - 2516
LID - 10.3389/fimmu.2019.02516 [doi]
LID - 2516
AB  - Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, 
      has been successfully used for stem cell mobilization and T cell immune tolerance 
      induction. The establishment of G-CSF-primed unmanipulated haploidentical blood 
      and marrow transplantation (The Beijing Protocol) has achieved outcomes for the 
      treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia 
      with haploidentical allografts comparable to those of human leukocyte antigen 
      (HLA)-matched sibling donor transplantation. Currently, G-CSF-mobilized bone 
      marrow and/or peripheral blood stem cell sources have been widely used in 
      unmanipulated haploidentical transplant settings. In this review, we summarize 
      the roles of G-CSF in inducing T cell immune tolerance. We discuss the recent 
      advances in the Beijing Protocol, mainly focusing on strategies that have been 
      used to improve transplant outcomes in cases of poor graft function, virus 
      infections, and relapse. The application of G-CSF-primed allografts in other 
      haploidentical modalities is also discussed.
CI  - Copyright (c) 2019 Chang, Zhao and Huang.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Peking University Institute of 
      Hematology, Peking University People's Hospital, Beijing, China.
FAU - Zhao, Xiang-Yu
AU  - Zhao XY
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Peking University Institute of 
      Hematology, Peking University People's Hospital, Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National 
      Clinical Research Center for Hematologic Disease, Peking University Institute of 
      Hematology, Peking University People's Hospital, Beijing, China.
AD  - Peking-Tsinghua Center for Life Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20191101
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - *Bone Marrow Transplantation
MH  - Granulocyte Colony-Stimulating Factor/*immunology
MH  - Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immune Tolerance
MH  - T-Lymphocytes/immunology
PMC - PMC6842971
OTO - NOTNLM
OT  - granulocyte colony-stimulating factor
OT  - haploidentical stem cell transplantation
OT  - poor graft function
OT  - relapse
OT  - virus infections
EDAT- 2019/11/22 06:00
MHDA- 2020/11/18 06:00
PMCR- 2019/01/01
CRDT- 2019/11/22 06:00
PHST- 2019/05/31 00:00 [received]
PHST- 2019/10/09 00:00 [accepted]
PHST- 2019/11/22 06:00 [entrez]
PHST- 2019/11/22 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.02516 [doi]
PST - epublish
SO  - Front Immunol. 2019 Nov 1;10:2516. doi: 10.3389/fimmu.2019.02516. eCollection 
      2019.